Merakris Therapeutics Announces FDA Clearance for Part 2 of its Phase II Multicenter Investigational New Drug Study of Dermacyte® Liquid Part 2 of the Phase II multicenter clinical study for the investigational wound care drug, Dermacyte® Amniotic Wound Care Liquid, will begin late 2024.

Merakris Therapeutics to Release Final Part 1 Data From Phase 2 Multicenter Investigational Drug Study for Dermacyte® Liquid Merakris to present encouraging Phase 2 clinical drug trial data at annual Treasure Hunt Podiatry and Wound Conference in Los Angeles, CA, February 24-25.

Merakris To Share Data from Fully Enrolled First Part of Two-Part Dermacyte® Liquid Clinical Trial Merakris Therapeutics announces it has fully enrolled the first part of a clinical trial to evaluate its investigational drug product, Dermacyte® Liquid.